Gentel Biosciences Powers Protein Research with New Proteomics Multi-System(TM)
MADISON, Wis.–(BUSINESS WIRE)–Gentel Biosciences, a leader in proteomics discovery tools, today launched the Gentel Proteomics Multi-System™ providing “scan-to-analysis” functionality for multiplex immunoassays, lysate and antigen arrays as well as Western Blot, ELISA and tissue imaging, delivering multi-application value to researchers worldwide.
Alex Vodenlich, Gentel’s CEO, said of the system, “The Gentel Proteomics Multi-System is a game-changer in terms of functionality and affordability. It allows researchers with minimal proteomics experience or labs with limited budgets to play at a level never seen before. Gentel provides more than just an assay platform with hardware and software. We are enabling a proteomics-application workhorse that delivers reliable, reproducible results, gets you answers, and advances your research. The Proteomics Multi-System truly opens the gateway to proteomics for the non-protein researcher through its flexibility and ease of use.”
The integrated Proteomics Multi-System includes a high-resolution scanner along with a laptop computer preconfigured with image-capture and analysis software capable of data extraction and quantitation. In addition, the system allows the use of Gentel’s flagship APiX™ chromogenic reagents and slides as well as non-fluorescent proteomics products from other leading vendors.
Dr. Harry Partidos, Senior Scientist at Inviragen, Inc., and his research team leverage the Gentel Proteomics Multi-System in the development of their vaccines that protect against emerging infectious diseases. “We needed a fast and easy method for measuring cytokine levels in mouse models and the Gentel Proteomics Multi-System was a great fit for us,” Dr. Partidos said. “Gentel’s kits and system provide us with a quick profile of immune response from our precious, small-volume samples. It’s a very practical way to measure 12 cytokines simultaneously,” stated Partidos.
To learn more about the power and flexibility of the new Proteomics Multi-System and to watch a short-summary presentation of how it can advance for your research, please visit www.proteomicsmultisystem.com.
About Gentel Biosciences, Inc.
Gentel’s mission is to deliver cost-effective, easy-to-use and reliable proteomics products and services that enable researchers to perform faster discovery, validation and screening of protein biomarkers. Gentel’s headquarters is located in Madison, Wisconsin. Please visit www.gentelbio.com for more information.
About Inviragen, Inc.
Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases worldwide. Inviragen’s lead product candidate is a vaccine to protect against dengue fever, a disease that threatens 3.6 billion people across the globe. Inviragen is also developing vaccines to protect against hand, foot and mouth disease and Japanese encephalitis, both of which affect millions of children in Asia. Vaccines in preclinical research stages include a chikungunya vaccine, a low-cost human papilloma virus vaccine, vaccines to protect against new forms of influenza and a vaccine to protect against West Nile for global health markets. Inviragen has offices in Fort Collins, Colorado, Madison, Wisconsin and Singapore. Please see www.inviragen.com for more details.
